Is serum-derived exosomal hTERT transcript a marker of oncogenic activity in primary brain tumors? An exploratory study.
Orit UzielAndrew A KannerEinat BeerySapir LevMeir LahavSuzana Horn-FichmanSagi Har NofYuseph LavivShlomit Yust KatzAlexandra AmielRamez Abu ShkaraMustafa SiddeeqAdva Levi-BardaPia RaananiYaron SelaZvi CohenTali SiegalPublished in: Cancer medicine (2023)
We demonstrated for the first time that the expression of e-hTERT-trans transcript can be measured in the serum of primary brain tumors. This exosomal marker carries the potential to serve as a biomarker once used in conjunction with other clinical and radiological parameters. Future studies are required to investigate whether the sensitivity could be augmented and whether it can be implemented into routine patients care.
Keyphrases
- end stage renal disease
- ejection fraction
- newly diagnosed
- healthcare
- chronic kidney disease
- poor prognosis
- rna seq
- prognostic factors
- peritoneal dialysis
- quality improvement
- transcription factor
- clinical practice
- current status
- risk assessment
- patient reported outcomes
- long non coding rna
- single cell
- patient reported